The global antifungal drugs market value was USD 14.8 billion in 2022, driven by the increasing prevalence of fungal infections across the globe. The global antifungal drugs market share is anticipated to grow at a CAGR of 3.7% during the forecast period of 2023-2031 to achieve a value of USD 20.6 billion by 2031.
North America: The largest market for antifungal drugs, driven by factors such as the advanced healthcare infrastructure, high prevalence of fungal infections, and significant investments in antifungal drug research.
Europe: The second-largest market, with increasing demand for antifungal drugs due to a growing aging population, a supportive regulatory framework, and an expanding pharmaceutical sector.
Asia Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing population, increasing prevalence of fungal infections, and growing investments in healthcare infrastructure and pharmaceutical research.
Growing geriatric population: The aging population is more susceptible to fungal infections due to their weakened immune systems, further fuelling the demand for antifungal medications.
Advancements in antifungal drug development: The development of new antifungal drugs with improved efficacy and safety profiles has contributed to market growth. Additionally, the emergence of drug resistance among certain fungal species has spurred research into new antifungal therapies.
Competitor Landscape of the Antifungal Drugs Market
The report gives an in-depth analysis of the key players involved in the antifungal drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
Antifungal Drugs Market: Introduction
Antifungal drugs are medications used to treat fungal infections, which can affect various parts of the body, including the skin, nails, mouth, lungs, and other organs. These infections can be caused by a wide range of fungi, including Candida, Aspergillus, and Cryptococcus species. Antifungal drugs work by inhibiting the growth of fungi or killing them outright. They are available in various forms, such as oral tablets, creams, ointments, and intravenous injections.Antifungal Drugs Market Scenario
The global market for antifungal drugs has witnessed significant growth in recent years, driven by factors such as the increasing prevalence of fungal infections, the growing geriatric population, and advancements in antifungal drug development.North America: The largest market for antifungal drugs, driven by factors such as the advanced healthcare infrastructure, high prevalence of fungal infections, and significant investments in antifungal drug research.
Europe: The second-largest market, with increasing demand for antifungal drugs due to a growing aging population, a supportive regulatory framework, and an expanding pharmaceutical sector.
Asia Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing population, increasing prevalence of fungal infections, and growing investments in healthcare infrastructure and pharmaceutical research.
Antifungal Drugs Market Segmentation
Market Breakup by Drug Class
Azoles
- Voriconazole
- Posaconazole
- Isavuconazole
- Others
Echinocandins
- Caspofungin
- Micafungin
- Others
Polyenes
- Amphotericin B
- Others
Allylamines
- Terbinafine
- Others
- Others
Market Breakup by Indication
- Dermatophytosis
- Aspergillosis
- Candidiasis
- Mucormysosis
- Others
Market Breakup by Dosage Form
- Oral
- Cream and Ointments
- Powders
- Injection
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Trends in the Antifungal Drugs Market
Increasing prevalence of fungal infections: The rising incidence of fungal infections, particularly among immunocompromised individuals, such as patients undergoing chemotherapy or organ transplant recipients, has led to a growing demand for antifungal drugs, driving market growth.Growing geriatric population: The aging population is more susceptible to fungal infections due to their weakened immune systems, further fuelling the demand for antifungal medications.
Advancements in antifungal drug development: The development of new antifungal drugs with improved efficacy and safety profiles has contributed to market growth. Additionally, the emergence of drug resistance among certain fungal species has spurred research into new antifungal therapies.
Competitor Landscape of the Antifungal Drugs Market
The report gives an in-depth analysis of the key players involved in the antifungal drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Abbott Laboratories
- GlaxoSmithKline PLC
- Novartis AG
- Pfizer Inc
- BAYER AG
- SANOFI
- MERCK & CO., INC
- ASTELLAS PHARMA, INC
- SCYNEXIS INC.
Table of Contents
1 Preface
3 Fungal Disease Overview
4 Patient Profile
5 Fungal Disease Epidemiology Analysis
6 Global Antifungal Drugs Market Overview
7 Global Antifungal Drugs Market Landscape
8 Antifungal Drugs Challenges and Unmet Needs
10 Global Antifungal Drugs Market Dynamics
11 Global Antifungal Drugs Market Segmentation
12 North America Antifungal Drugs Market
13 Europe Antifungal Drugs Market
14 Asia Pacific Antifungal Drugs Market
15 Latin America Antifungal Drugs Market
16 Middle East and Africa Antifungal Drugs Market
17 Patent Analysis
18 Grants Analysis
19 Clinical Trials Analysis
20 Funding Analysis
21 Partnership and Collaborations Analysis
22 Regulatory Framework
23 Supplier Landscape
24 Global Antifungal Drugs Market- Distribution Model (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
27 Payment Methods (Additional Insight)
Companies Mentioned
- Abbott Laboratories
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Inc.
- Bayer AG
- Sanofi
- Merck & Co. Inc.
- Astellas Pharma, Inc.
- Scynexis Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | April 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 15.4 Billion |
| Forecasted Market Value ( USD | $ 20.6 Billion |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
